Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Clinical Trials

Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)

Phase 3

Completed

Conditions: Dermatitis, Atopic

Interventions: Drug: Matching Placebo
Drug: Dupilumab

First Posted Date: 2017-11-17

Last Posted Date: 2020-08-13

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 367

Registration Number: NCT03345914

Locations: 🇬🇧
Regeneron Research Site, Sheffield, United Kingdom

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

Phase 2

Completed

Conditions: Dermatitis, Atopic

Interventions: Drug: Dupilumab
Drug: Matching placebo

First Posted Date: 2017-11-17

Last Posted Date: 2022-07-28

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 202

Registration Number: NCT03346434

Locations: 🇩🇪
Regeneron Investigational site, Muenchen, Germany
🇬🇧
Regeneron Investigational Site, Sheffield, South Yorkshire, United Kingdom

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

Phase 3

Completed

Conditions: Osteoarthritis, Knee
Osteoarthritis, Hip

Interventions: Other: Diclofenac
Other: Celecoxib
Drug: Fasinumab
Drug: Matching placebo

First Posted Date: 2017-10-09

Last Posted Date: 2023-02-24

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 1650

Registration Number: NCT03304379

Locations: 🇺🇸
Advance Research Center, Anaheim, California, United States
🇺🇸
Catalina Research Institute, LLC, Montclair, California, United States
🇺🇸
Clinical Research Advantage, Inc./Warner Family Practice, PC, Chandler, Arizona, United States

and more 66 locations

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee

Phase 3

Terminated

Conditions: Chronic Low Back Pain
Osteoarthritis

Interventions: Drug: Placebo
Drug: Fasinumab

First Posted Date: 2017-09-18

Last Posted Date: 2021-06-30

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 63

Registration Number: NCT03285646

Locations: 🇺🇸
Regeneron Research Site #1, Memphis, Tennessee, United States
🇺🇸
Regeneron Research Site, Kenosha, Wisconsin, United States
🇺🇸
Regeneron Research Site #2, Memphis, Tennessee, United States

Study of Cemiplimab in Adults With Cervical Cancer

Phase 3

Completed

Conditions: Squamous Cell Carcinoma (SCC)
Recurrent or Metastatic, Platinum-refractory Cervical Cancer

Interventions: Drug: Cemiplimab
Drug: Investigator Choice (IC) Chemotherapy

First Posted Date: 2017-08-22

Last Posted Date: 2025-04-08

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 608

Registration Number: NCT03257267

Locations: 🇺🇸
First Health of the Carolinas Outpatient Cancer Center, Pinehurst, North Carolina, United States
🇧🇷
Liga Norte Riograndense Contra o Câncer, Natal, Rio Grande Do Norte, Brazil
🇧🇷
Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil

and more 101 locations

Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

Phase 1

Active, not recruiting

Conditions: Advanced Malignancies

Interventions: Drug: Cemiplimab
Drug: Ipilimumab
Drug: Fianlimab
Drug: Platinum-doublet chemotherapy
Drug: Gemcitabine
Drug: Paclitaxel
Drug: Pemetrexed

First Posted Date: 2017-07-28

Last Posted Date: 2025-04-02

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 146

Registration Number: NCT03233139

Locations: 🇯🇵
National Cancer Center Hospital - Tsukiji Campus, Chuo ku, Tokyo, Japan
🇯🇵
Saitama Cancer Center, Ina, Saitama, Japan
🇯🇵
National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan

and more 17 locations

An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)

Phase 1

Completed

Conditions: Recurrent Squamous Cell Carcinoma of Neck
Metastatic Squamous Cell Carcinoma of Head
Recurrent Squamous Cell Carcinoma of Head
Metastatic Squamous Cell Carcinoma Neck

Interventions: Drug: REGN2810

First Posted Date: 2017-06-23

Last Posted Date: 2020-03-19

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 33

Registration Number: NCT03198130

Locations: 🇰🇷
Seoul National University, Seoul, Korea, Republic of
🇰🇷
Yonsei University College of Medicine, Severence Hospital, Seoul, Korea, Republic of
🇬🇧
University Birmingham, Birmingham, United Kingdom

and more 3 locations

A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva

Phase 2

Completed

Conditions: Fibrodysplasia Ossificans Progressiva

Interventions: Drug: REGN2477
Drug: Matching placebo

First Posted Date: 2017-06-15

Last Posted Date: 2022-12-02

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 44

Registration Number: NCT03188666

Locations: 🇮🇹
Giannina Gaslini Institute, Genova, Italy
🇫🇷
Hopital Lariboisiere,Hospitalier Universitaire Nord, Paris, France
🇫🇷
Hopital Cochin, Paris, France

and more 8 locations

Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

Phase 2

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Matching placebo
Drug: Evinacumab
Other: Background Lipid Modifying Therapy (LMT)

First Posted Date: 2017-06-05

Last Posted Date: 2023-02-10

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 272

Registration Number: NCT03175367

Locations: 🇮🇹
Azienda Ospedaliero Universitaria Federico II di Napoli, Napoli, Italy
🇮🇹
Dipartimento di Medicina Traslazionale e di Precisione dell'Università degli Studi di, Rome, Italy
🇺🇸
Office of Dr. John D Homan MD, Newport Beach, California, United States

and more 92 locations

A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

Phase 3

Completed

Conditions: Osteoarthritis, Knee
Osteoarthritis, Hip

Interventions: Drug: Fasinumab
Drug: Fasinumab-matching placebo
Drug: Naproxen
Drug: Naproxen-matching placebo

First Posted Date: 2017-05-19

Last Posted Date: 2022-11-14

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 3307

Registration Number: NCT03161093

Locations: 🇺🇸
Pacific Arthritis Care Center, Los Angeles, California, United States
🇺🇸
Lynn Institute of the Rockies, Colorado Springs, Colorado, United States
🇺🇸
Panorama Orthopedics & Spine Center, Golden, Colorado, United States

and more 129 locations

Home Terms & Conditions Privacy Policy